RET and non-small cell lung carcinoma: The ARROW study of pralsetinib in RET fusion-positive NSCLC showed an ORR of 72% in treatment-naïve patients and 59% in previously treated patients.29 Similarly, selpercatinib reported an ORR of 84% in treatment-naïve patients in the LIBRETTO-431 study30 and 61% in previously treated patients in the LIBRETTO-001 study.28